Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19

Biovista, a privately-held AI / bioscience firm best known for drug repositioning, has identified four treatments – two prescription drugs and two over-the-counter compounds -- to counter key symptoms of COVID-19. "Drug AI helps find that needle in the haystack, and we are optimistic that we have found four of them to start," said Aris Persidis, Biovista's President and Co-Founder. The first drug has the potential to reduce viral replication, limit inflammatory events, and help protect against acute lung injury. The second drug has the potential to reduce viral load, improving the primary ARDS component of the disease and reducing the cytokine storm in COVID-19. "These compounds won't cure COVID-19, but appear able, based on their mechanism of action, to limit the damage," said Dr. Eftychia Lekka, Senior Investigator, Drug Discovery.